Last reviewed · How we verify
Bupivacaine Liposomes(BL)
Bupivacaine liposomes is a long-acting local anesthetic formulation that delivers bupivacaine encapsulated in lipid vesicles to provide prolonged nerve blockade and pain relief.
Bupivacaine liposomes is a long-acting local anesthetic formulation that delivers bupivacaine encapsulated in lipid vesicles to provide prolonged nerve blockade and pain relief. Used for Local anesthesia and analgesia for surgical procedures, Postoperative pain management.
At a glance
| Generic name | Bupivacaine Liposomes(BL) |
|---|---|
| Sponsor | Huazhong University of Science and Technology |
| Drug class | Local anesthetic (liposomal formulation) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Pain Management |
| Phase | FDA-approved |
Mechanism of action
Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials. By encapsulating bupivacaine in liposomal carriers, the formulation extends the drug's duration of action, allowing for sustained anesthetic effect over an extended period compared to conventional bupivacaine solutions.
Approved indications
- Local anesthesia and analgesia for surgical procedures
- Postoperative pain management
Common side effects
- Injection site reactions
- Transient neurological symptoms
- Systemic toxicity (at high doses)
Key clinical trials
- Bupivacaine Liposomes or Bupivacaine for CMB on Postoperative Analgesia in Laparoscopic Hepatobiliary Pancreatic Surgery (PHASE4)
- Determination of the Optimal Volume of 0.5% Bupivacaine Liposome in Single-Injection Interscalene Brachial Plexus Block: A Bayesian Phase I/II Trial
- Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupivacaine Liposomes(BL) CI brief — competitive landscape report
- Bupivacaine Liposomes(BL) updates RSS · CI watch RSS
- Huazhong University of Science and Technology portfolio CI